572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial.
Saved in:
| Title: | 572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial. |
|---|---|
| Authors: | Gennari, A.1 (AUTHOR), Nardin, S.2 (AUTHOR), Brain, E.G.C.3 (AUTHOR), Piccardo, A.4 (AUTHOR), De Censi, A.5 (AUTHOR), Matteucci, F.6 (AUTHOR), Wuerstlein, R.7 (AUTHOR), Seban, R.8 (AUTHOR), Fiz, F.4 (AUTHOR), Ruffilli, B.1 (AUTHOR), Bottoni, G.4 (AUTHOR), Sacchetti, G.M.9 (AUTHOR), Fontana, V.10 (AUTHOR), Dip, B.9 (AUTHOR), Nanni, O.11 (AUTHOR), Palleschi, M.12 (AUTHOR), Rossi, V.2 (AUTHOR), D'Avanzo, F.2 (AUTHOR), Boni, L.10 (AUTHOR), Harbeck, N.7 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS445-S446. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.994 |
